|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM25A |
Gene summary for FAM25A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM25A | Gene ID | 643161 |
| Gene name | family with sequence similarity 25 member A | |
| Gene Alias | bA96C23.5 | |
| Cytomap | 10q23.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | B3EWG3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 643161 | FAM25A | C04 | Human | Oral cavity | OSCC | 1.83e-03 | 2.23e-01 | 0.2633 |
| 643161 | FAM25A | LP15 | Human | Oral cavity | LP | 8.35e-03 | 3.04e-01 | 0.2174 |
| 643161 | FAM25A | SYSMH3 | Human | Oral cavity | OSCC | 2.21e-25 | 5.12e-01 | 0.2442 |
| 643161 | FAM25A | SYSMH4 | Human | Oral cavity | OSCC | 1.59e-05 | 1.03e-01 | 0.1226 |
| 643161 | FAM25A | SYSMH5 | Human | Oral cavity | OSCC | 1.38e-24 | 5.49e-01 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM25A | SNV | Missense_Mutation | c.31N>A | p.Glu11Lys | p.E11K | B3EWG3,B3EWG4 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.81) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FAM25A | SNV | Missense_Mutation | novel | c.54N>T | p.Glu18Asp | p.E18D | B3EWG3,B3EWG4 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.801) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM25A | SNV | Missense_Mutation | novel | c.181N>G | p.Lys61Glu | p.K61E | B3EWG3,B3EWG4 | protein_coding | deleterious_low_confidence(0.02) | benign(0.077) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM25A | SNV | Missense_Mutation | c.31G>A | p.Glu11Lys | p.E11K | B3EWG3,B3EWG4 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.81) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM25A | SNV | Missense_Mutation | novel | c.149N>T | p.Ala50Val | p.A50V | B3EWG3,B3EWG4 | protein_coding | tolerated_low_confidence(0.2) | benign(0.003) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM25A | SNV | Missense_Mutation | novel | c.230T>A | p.Ile77Asn | p.I77N | B3EWG3,B3EWG4 | protein_coding | deleterious_low_confidence(0) | benign(0.106) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| FAM25A | SNV | Missense_Mutation | novel | c.148G>T | p.Ala50Ser | p.A50S | B3EWG3,B3EWG4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.08) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM25A | SNV | Missense_Mutation | novel | c.183G>T | p.Lys61Asn | p.K61N | B3EWG3,B3EWG4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.113) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |